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Background: It has traditionally been assumed that peanut
allergy is rarely outgrown.
Objective: The goal of this study was to determine the number
of children with peanut allergy who become tolerant of peanut. 
Methods: Patients aged 4 to 20 years with a diagnosis of
peanut allergy were evaluated by questionnaire, skin testing,
and a quantitative antibody fluorescent-enzyme immunoassay.
Patients who had been reaction free in the past year and had a
peanut IgE (PN-IgE) level less than 20 kilounits of antibody
per liter (kUA/L) were offered an open or double-blind, place-
bo-controlled peanut challenge.
Results: A total of 223 patients were evaluated, and of those,
85 (PN-IgE < 0.35-20.4 kUA/L [median 1.42 kUA/L]) partici-
pated in an oral peanut challenge. Forty-eight (21.5%) patients
had negative challenge results and were believed to have out-
grown their peanut allergy (aged 4-17.5 years [median 6
years]; PN-IgE < 0.35-20.4 kUA/L [median 0.69 kUA/L]). Thir-
ty-seven failed the challenge (aged 4-13 years [median 6.5
years]; RAST < 0.35-18.2 kUA/L [median 2.06 kUA/L]). Forty-
one patients with PN-IgE levels less than 20 kUA/L declined to
undergo challenge, and 97 were not eligible for challenge
because their PN-IgE levels were greater than 20 kUA/L or
they had had a recent reaction. Sixty-seven percent of patients
with PN-IgE levels less than 2 kUA/L and 61% with levels less
than 5 kUA/L had negative challenge results. Of those who
underwent challenge, PN-IgE levels for those who passed ver-
sus those who failed were different at the time of challenge
(P = .009), but not at the time of diagnosis (P = .25).
Conclusion: This study demonstrates that peanut allergy is
outgrown in about 21.5% of patients. Patients with low PN-
IgE levels should be offered a peanut challenge in a medical
setting to demonstrate whether they can now tolerate peanuts.
(J Allergy Clin Immunol 2001;107:367-74.)
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The diagnosis of peanut allergy carries with it great
medical and emotional significance.1,2 Patients and their
families are advised to be extremely cautious with all
foods consumed and that peanut allergy reactions can be
severe and even fatal. With less red meat being consumed
and health foods, vegetarianism, and prepared foods
becoming more prevalent, peanut is more commonly used
as a source of protein. This leads to both an increased risk
of exposure as well as possible nutritional consequences.
Food allergy is very common in the first 3 years of life,
with up to 6% to 8% of children being affected.3 Longi-
tudinal studies have shown that most food allergies that
begin early in life, such as to egg and cow’s milk, typi-
cally resolve over time. Up to 80% of infants with egg
allergy are able to consume egg by 5 years of age, and up
to 85% of children with cow’s milk allergy are tolerant of
milk by 3 years of age.4-6 Although it was previously
thought that virtually all peanut sensitivity was lifelong,
anecdotal observations have suggested that some chil-
dren do in fact outgrow their allergy. In addition, a recent
report from the United Kingdom on the natural history of
peanut allergy in a small population found that 9.6% of
peanut allergic children appeared to have lost their sensi-
tivity over time.7 
In this study we sought to determine the frequency with
which peanut allergy is outgrown and any characteristics
that might predict this tendency. We identified patients
with a history of peanut allergy and investigated their ini-
tial and subsequent reactions to peanut, as well as their his-
tory of other atopic diseases, through chart review and a
detailed questionnaire. Subsequently, skin testing to
peanut and quantification of peanut-specific IgE (PN-IgE)
levels were performed. Those who met preset criteria were
invited to undergo an oral peanut challenge. In addition,
we attempted to determine the efficacy of the CAP System
quantitative antibody fluorescent-enzyme immunoassay
(FEIA; Pharmacia, Uppsala, Sweden) in predicting chal-
lenge outcome in this population of patients.
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METHODS
Study population
From January 1998 to March 2000, patients 4 years and older
with a diagnosis of peanut allergy were identified by review of charts
from the Johns Hopkins Pediatric Allergy Clinic, the Arkansas Chil-
dren’s Hospital Pediatric Allergy Clinic, and a private allergy office.
Patients were determined to have peanut allergy if they had a histo-
ry of an acute reaction to peanut ingestion and positive results to a
skin test, RAST, or challenge, or in some cases, positive results to
RAST or a skin test for peanut with no history of ever ingesting
peanut. Patients whose PN-IgE levels were higher than 20 kilounits
of antibody per liter (kUA/L) or who had had a reaction in the prior
year were classified as having ongoing peanut allergy and were not
studied further. All other patients were enrolled in the following
study protocol, which was approved by the investigational review
boards of the Johns Hopkins University School of Medicine and the
University of Arkansas for Medical Sciences College of Medicine. 
Patients accompanied by their parents were seen in the Clinical
Research Center at Johns Hopkins Hospital or the Arkansas Chil-
dren’s Hospital. A questionnaire was administered to establish a
detailed clinical history, including the age of onset of the peanut
allergy, the characteristics of all prior peanut reactions, any other
food allergies and their resolution or lack of resolution, and any his-
tory of other atopic diseases. Antihistamines (short acting, 72 hours;
long acting, 7 days) were restricted before the first visit and the food
challenges. Unless there was objection by the family or a history of
severe anaphylaxis to peanuts, a puncture skin test to peanut was
performed. Patients with a PN-IgE level of less than 20 kUA/L who
had only cutaneous symptoms after peanut ingestion were asked to
participate in an oral peanut challenge. In patients with a history of
a severe reaction, a PN-IgE level of 10 kUA/L was used as the cut-
off for challenge eligibility. Both double-blind, placebo-controlled
and open food challenges were used during the course of the study.
Diagnosis of other food allergies
Other food allergies, such as to milk or egg, were diagnosed if
patients had both a history of an acute reaction to that food and a
positive skin test or RAST result, or if they had a food-specific IgE
level above that determined to be greater than 95% predictive of a
positive challenge result to that food.8 Tree nut allergy was diag-
nosed if patients had a history of an acute reaction and/or a positive
skin test or RAST result to 1 or more tree nuts. Wheat, soy, or other
legume allergies or other less common food allergies (eg, mustard)
were diagnosed only if patients had a positive challenge result or
both a clinical reaction and a positive skin test or RAST result. 
Laboratory studies
Puncture skin tests. Puncture skin tests were performed through
a standard technique with a Wyeth needle (Becton Dickinson Co,
Baltimore, Md). A glycerinated peanut extract (1:20; Greer Labora-
tories, Lenoir, NC) and positive (histamine) and negative (saline
solution) controls were applied. The mean diameters of both the
wheal and erythema were measured after 15 minutes. To be consid-
ered positive, the wheal had to be at least 3 mm greater than that of
the negative control. A scoring system was used that compared each
patient’s peanut result to his or her histamine result as follows: 0, no
wheal present; 1+, wheal less than half of the histamine diameter;
2+, wheal greater than or equal to half of the histamine diameter;
3+, wheal equal to histamine diameter; 4+, wheal greater than his-
tamine diameter but less than 2 times the histamine diameter; and
5+, wheal greater than or equal to 2 times the histamine diameter.
CAP-RAST System FEIA. Venous serum samples were analyzed
for circulating IgE to peanut with the CAP-System FEIA. After the
samples were obtained, the serum was separated and stored at
–20°C until analysis. The assay had a lower limit of detection of
0.35 kUA/L and an upper limit of 100 kUA/L, with higher values
simply reported as greater than 100 kUA/L.
Peanut challenges For the double-blind, placebo-controlled
peanut challenges (DBPCPCs), 4 g of peanut protein was disguised
in 84 g of either milk-free chocolate or ground chicken/turkey with
barbecue sauce. As a texture and flavor control, oatmeal was used
in the placebo. A physician or nurse who was blinded to the testing
material administered the challenge in 6 divided doses given every
15 minutes. The first dose contained 0.2 g of peanut protein (5% of
the challenge), and subsequent doses were increased to 0.4 g (10%),
0.6 g (15%), 0.8 g (20%), 1.0 g (25%), and 1.0 g (25%). The active
and placebo challenges were performed on 2 separate days. After
each challenge the patient was observed for 4 hours. Reactions were
recorded as to type, severity, time of onset, and duration. At any sign
of objective or subjective symptoms deemed clinically significant,
the challenge was terminated, and appropriate medical treatment
was administered. The nutrition department of the Pediatric Clinical
Research Unit prepared and randomized each challenge. All nega-
tive challenge results were confirmed by an open challenge, which
consisted of ingestion of 8 g of peanut in the form of peanut butter
or peanuts in candy. For the open challenges, the equivalent dose of
peanut protein as peanut butter was mixed in juice, and the chal-
lenge was performed with the same increasing dose schedule
described previously. 
Statistical analysis
For analysis, patients were separated into the following 4 cate-
gories: patients who passed the peanut challenge, patients who
failed the challenge, patients who refused to be challenged although
they did meet the eligibility requirements, and those who were
unable to be challenged because they had PN-IgE levels greater
than 20 kUA/L or a recent history of reaction. In addition to com-
paring patients who passed the challenge with those who failed,
patients who passed the challenge were compared with patients who
had ongoing peanut allergy, defined as those who could not be chal-
lenged plus those who failed the challenge.
PN-IgE concentrations, as determined by the CAP-System FEIA,
were compared by use of the Mann-Whitney U test. The frequencies
of asthma, allergic rhinitis, atopic dermatitis, and other food allergies
in these groups were compared by use of the χ2 test. The perfor-
mance characteristics of the CAP-System FEIA, including sensitivi-
ty, specificity, positive predictive value (PPV), and negative predic-
tive value (NPV), were calculated with PN-IgE cutoff values of 0.35
kUA/L (the lower limit of detection), 2 kUA/L, and 5 kUA/L.
RESULTS
A total of 223 patients in whom peanut allergy had
been diagnosed, with an age range at the time of evalua-
tion of 4 to 20 years (median 6.5 years), participated in
the study (Table I); 212 patients were evaluated at Johns
Hopkins and 11 at Arkansas Children’s Hospital. There
were 140 male (63%) and 83 female (37%) patients, and
peanut allergy had been diagnosed in each between the
ages of 2 months and 15 years (median 1.5 years). The
initial diagnosis was made on the basis of a history of an
acute reaction to peanut in 167 patients, 164 of whom
also had a positive skin test and/or RAST result. Of the
remaining 66 patients, 11 had diagnoses based on posi-
tive skin test or RAST results and a marked improvement
in atopic dermatitis with a peanut-restricted diet; 54 who
were never known to have ingested peanuts were diag-
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nosed by only a positive skin test or RAST result (8 of
whom subsequently did have acute reactions), and 1 had
a positive skin test result and a PN-IgE level greater than
20 kUA/L but had a history of accidental peanut ingestion
without reaction. The racial distribution was as follows:
182 white (81%), 29 African American (13%), 10 Asian
American (5%), and 2 Hispanic (1%). The initial diagno-
sis was made by skin test in 117 patients (52.5%), by
RAST in 66 patients (29.6%), by both skin test and
RAST in 37 patients (16.6%), by history in 1 patient
(0.4%), and by food challenge in 2 patients (0.9%). 
On the basis of the history and PN-IgE levels, 126
patients were eligible for a peanut challenge. Forty-one
patients (16 female and 25 male), ranging in age from 4
to 16.5 years (median 7 years), declined further partici-
pation in the study and did not undergo challenge. The
PN-IgE levels of these patients ranged from <0.35 to
16.9 kUA/L (median 4.98 kUA/L). The remaining 85
patients (31 female and 54 male), aged from 4 to 17.5
years (median 6 years), participated in either a DBPCPC
(33%) or open peanut challenge (67%). The PN-IgE lev-
els of the patients challenged ranged from <0.35 to 20.4
kUA/L (median 1.42 kUA/L). The age at diagnosis for the
group challenged ranged from 6 months to 12 years
(median 1.5 years), and the initial PN-IgE levels (drawn
at diagnosis or at <2 years of age), which were available
for 30 patients, ranged from <0.35 to 52.9 kUA/L (medi-
an 2.9 kUA/L). 
The peanut challenge results were negative in 48
patients (21.5% of the 223 patients), who ranged in age
from 4 to 17.5 years (median 6 years). As seen in Table I
and Fig 1, PN-IgE levels for those who had negative
challenge results ranged from <0.35 to 20.4 kUA/L
(median 0.69 kUA/L), compared with <0.35 to 18.2
kUA/L (median 2.06 kUA/L) in the group who reacted (P
= .009). Seventy-three percent of children with a negative
RAST results (<0.35 kUA/L), 67% with PN-IgE levels
less than 2.0 kUA/L, and 61% with PN-IgE levels less
than 5.0 kUA/L had negative challenge results. The age
of diagnosis for those who passed the challenge (8
months to 12 years, median 1.5 years) was not signifi-
cantly different from that of those who failed (6 months
to 4 years, median 1.5 years; P = .083). Initial PN-IgE
levels, available in 16 of the 48 patients who passed the
challenge, were not different from those of patients who
failed, available in 14 of 37 patients (2.2 vs 2.91 kUA/L,
P = .25) (Fig 2). Only 2 of the 54 patients with initial PN-
IgE levels greater than 10 kUA/L outgrew their peanut
allergy (levels of 10.4 and 52.9 kUA/L, respectively).
In patients who were unable to be challenged, PN-IgE
levels ranged from 18.2 to 100 kUA/L (median > 100
kUA/L) (Fig 1). Initial PN-IgE levels, available in 52 of
these 97 patients, ranged from 4.5 to >100 kUA/L (medi-
an > 100 kUA/L) (Fig 2). Both the current and initial PN-
IgE levels of patients who were unable to be challenged,
as well as those with ongoing peanut allergy (patients
who failed challenge plus those unable to be challenged),
were significantly higher than the levels of those who
passed the challenge (all P values < .0001).
Sixty-six patients whose allergies had been diagnosed
by skin test or RAST alone initially did not have a clini-
cal history of either an acute reaction or exposure to
peanuts. Broken down by group, of the 13 patients whose
allergies were initially diagnosed by skin or RAST test-
ing alone and who passed the peanut challenge, 11 had
no history of peanut ingestion, 1 had a subsequent posi-
tive challenge result before passing this challenge, and 1
had accidental peanut ingestion without reaction (RAST
20.4 kUA/L). Of the 8 patients who failed the challenge,
7 had no history of peanut ingestion, and 1 had a subse-
quent reaction to peanut before the challenge. In the 27
patients who were unable to be challenged, 18 had no
TABLE I. Patient characteristics
Passed challenge Failed challenge Unable to be challenged Refused challenge Total
(n = 48) (n = 37) (n = 97) (n = 41) (n = 223)
Male (%) 28 (58) 26 (70) 61 (63) 25 (61) 140 (63)
Female (%) 20 (42) 11 (30) 36 (37) 16 (39) 83 (37)
Current age (y)
Range 4-17.5 4-13 4-20 4-16.5 4-20
Median 6 6.5 7 7 6.5
Current PN-IgE (kUA/L)
Range <0.35- 20.4 <0.35- 18.2 16.8-> 100 <0.35-16.9 <0.35->100
Median 0.69 2.06 >100 4.98 10.7
No. diagnosed by 11/34/2 11/18/6 31/49/17 13/16/12 66/117/37
RAST/skin test/both
No. diagnosed by 1/0 0/2 0/0 0/0 1/2
history/challenge
Age at diagnosis
Range 8 mo to 12 y 6 mo to 4 y 2 mo to 10 y 8 mo to 15 y 2 mo to 15 y
Median (y) 1.5 1.5 1.5 2 1.5
PN-IgE at diagnosis (kUA/L)
Range <0.35-52.9 1.8-24.4 4.5->100 0.64->100 <0.35->100 
Median 2.2 2.91 >100 6.27 19.8
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history of peanut ingestion, 4 had a subsequent reaction
to peanut ingestion, and 6 had marked improvement in
their atopic dermatitis with a peanut-restricted diet. In the
18 patients who refused the challenge, 10 had no history
of peanut ingestion, 5 had marked improvement in atopic
dermatitis with a peanut-restricted diet, and 3 had subse-
quent reactions to peanut ingestion. 
Skin tests were performed in 23 of 48 patients who
passed the challenge and 21 of 37 patients who failed
(Table II). Skin tests were positive in 15 of 23 (63%)
patients who passed the challenge, with 13 having a skin
test grade of 3+ or above. Nineteen of 21 (90%) patients
who failed the challenge had a positive skin test grade of
2+ or above. Of the 10 patients who had negative skin
test results, 2 had positive challenge results.
Initial reactions to peanut exposure are described in
Table III. Forty-four percent of patients had involvement
of the skin only. Of these, 19% had a rash on the face only,
6% had an acute eczematous rash, and 19% had hives
and/or angioedema. A few patients had initial reactions
involving only the respiratory or gastrointestinal systems
(2% and 4%, respectively), whereas 9% had involvement
of 2 systems, and 11% had involvement of 3 systems.
Patients who had negative peanut challenge results were
significantly more likely to have had an initial reaction
with involvement of only the skin than those with ongo-
ing peanut allergy (P = .03). Although patients with ongo-
ing peanut allergy were more likely to have had an initial
reaction involving all 3 systems (P = .03), 1 child with
involvement of all 3 systems did outgrow his allergy.
Eighty-eight percent of patients had 1 or more atopic
disorder other than food allergy (Table IV). Fifty-nine
percent had asthma, 60% had allergic rhinitis, 58% had
atopic dermatitis, 76% had a history of food allergy to a
food other than peanut, and 5% had no atopic disease
other than peanut allergy. Similar rates of asthma and
allergic rhinitis were observed in the patients who passed
and failed the challenge, as well as in those who were
unable to be challenged. However, patients who outgrew
their allergies had a lower rate of atopic dermatitis than
those who failed the challenge and those with ongoing
peanut allergy (P = .04 and .06, respectively).
Examination of associated food allergies revealed that
76% of the 223 patients had a history of another food aller-
gy, with similar rates observed in each group of patients
(Table V). The most common associated food allergies
were egg (55%), milk (41%), and tree nuts (40%). In addi-
tion, 15% of the patients had allergy to soy and 4% to
another legume. Comparison of patients who passed the
FIG 1. Current PN-IgE levels in patients who passed the challenge, who failed the challenge, or who were
unable to be challenged.
TABLE II. Comparison of skin test results for patients
undergoing peanut challenge
Passed challenge Failed challenge
Skin test result (n = 23) (n = 21)
0 8 2
1+ 2 0
2+ 0 1
3+ 9 5
4+ 4 6
5+ 0 7
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challenge with those who had ongoing peanut allergy
revealed that the patients with tree nut allergy tended to be
less likely to outgrow their peanut allergy (P = .058). 
Of the patients who had negative peanut challenge
results, 42% had outgrown at least 1 other food allergy,
compared with 51% of the patients who failed the chal-
lenge and 29% of those who were unable to be chal-
lenged (P = .04, passed challenge vs ongoing peanut
allergy). In addition, although 50% of patients who out-
grew peanut allergy had a history of egg allergy, only
19% currently carry this diagnosis, compared with 40%
of those with ongoing peanut allergy (P < .005). 
Seventy percent of the patients have ongoing allergies
to foods other than peanut (Table V). Thirty-nine percent
have egg allergy, 30% have milk allergy, and 39% have
tree nut allergy. The incidences of soy and other legume
allergy decreased to 6% and 3%, respectively. The cur-
rent prevalence of other food allergies was slightly dif-
ferent between the groups, with 58% of those who passed
the challenge remaining allergic to other foods, com-
pared with 54% and 77% of those who failed the chal-
lenge and who were unable to be challenged (P = .035,
passed challenge vs ongoing peanut allergy). 
The ability of the CAP-System FEIA to predict chal-
lenge outcome was analyzed with 3 different levels of
PN-IgE (Table VI). A PN-IgE of more than 0.35 kUA/L
had a sensitivity of 83.8%, a specificity of 33.3%, a PPV
of 49.2%, and an NPV of 72.7%. If a cutoff value of 2
kUA/L was used, the sensitivity was 54.1%, the speci-
ficity was 72.7%, the PPV was 60.6%, and the NPV was
67.3%. When 5 kUA/L was used as the cutoff, the sensi-
tivity was 24.3%, the specificity was 89.6%, and the PPV
and NPV were 64.3% and 60.6%, respectively. 
DISCUSSION
It is clear from this study that a subset of children do
indeed outgrow their peanut allergy. Although this is con-
trary to the traditional view of peanut allergy,2 it is most
likely not a new phenomenon. In the past, when there was
generally less awareness regarding peanut allergy among
both primary caretakers and parents, children who may
have had a reaction to peanut were typically advised to
avoid the food for 1 to 2 years and then reintroduce it at
home. Those who had another reaction very likely did
have life-long peanut allergy, and those who did not react
never came to medical attention. Now, however, it is more
common for children to be referred for evaluation after
their initial reaction, so that we are now seeing more chil-
dren with the short-lived variety of peanut allergy. 
Although it is certain that peanut allergy can be out-
grown, our result of 21.5% could be either an overesti-
mate or underestimate for several reasons. First, although
126 patients qualified for a challenge, only 85 elected to
participate in the challenge. Although the patients who
declined challenge tended to have higher PN-IgE levels
(median 4.98 kUA/L) than those who were challenged,
many had very low PN-IgE levels and even negative skin
test results. Because these patients were used in the
denominator to calculate the final result, the estimate of
21.5% is almost certainly an underestimate. Second,
although most of the children who were not challenged
FIG 2. Initial PN-IgE levels in patients who passed the challenge, who failed the challenge, or who were
unable to be challenged.
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because of high PN-IgE levels were likely to be peanut
allergic, at least a few could have passed a challenge.
Third, the patients included in this study may not be typ-
ical of all patients with peanut allergy in that they were
being seen in tertiary-care facilities, which was further
suggested by the very high percentage of patients with
multiple food allergies. Finally, open peanut challenges
were conducted in two thirds of the patients, and some of
the positive challenge results could have been due to
physiologic stress rather than true allergic reactivity.
Conversely, the result could be an overestimate
because of the inclusion of patients whose allergies were
TABLE III. Characteristics of initial peanut reactions
Passed challenge Failed challenge Unable to be challenged Refused challenge Total
(%) (%) (%) (%) (%)
Rash or hives on face only 13 (27) 9 (24) 18 (18) 3 (7) 43 (19)
Eczema 2 (4) 1 (3) 7 (7) 3 (7) 13 (6)
Hives/angioedema 14 (29) 10 (27) 12 (12) 6 (15) 42 (19)
Respiratory only 1 (2) 1 (3) 3 (3) 0 (0) 5 (2)
GI only 1 (2) 2 (5) 4 (4) 1 (2) 8 (4)
Skin and respiratory 2 (4) 1 (3) 6 (6) 3 (7) 12 (6)
Skin and GI 0 (0) 2 (5) 4 (4) 1 (2) 7 (3)
GI and respiratory 1 (2) 1 (3) 1 (1) 0 (0) 3 (1)
All 3 systems 1 (2) 2 (5) 15 (17) 6 (15) 24 (11)
Positive SPT or RAST only 13 (27) 8 (22) 27 (28) 18 (44) 66 (30)
GI, Gastrointestinal; SPT, skin prick test.
TABLE IV. Associated atopic disorders
Passed challenge Failed challenge Unable to be challenged Refused challenge Total
(%) (%) (%) (%) (%)
Asthma 26 (54) 17 (46) 60 (62) 28 (68) 131 (59)
Allergic rhinitis 27 (56) 19 (51) 58 (60) 30 (73) 134 (60)
Atopic dermatitis 22 (46) 25 (68) 57 (59) 26 (63) 130 (58)
Current other food allergies 28 (58) 20 (54) 75 (77) 36 (88) 159 (70)
History of other food allergies 32 (67) 25 (68) 77 (79) 36 (88) 170 (76)
Outgrown food allergies 20 (42) 19 (51) 28 (29) 13 (32) 80 (36)
No atopic disorder except food 5 (10) 5 (14) 5 (5) 1 (2) 16 (7)
allergy (other than peanut)
No other atopic disorder 4 (8) 2 (5) 3 (3) 1 (2) 10 (5)
TABLE V. Other food allergy
History/challenge
Passed challenge Failed challenge Unable to be challenged Refused challenge Total
Food (n = 48) (n = 37) (n = 97) (n = 41) (n = 223)
Milk 15/10 17/8 42/34 17/15 91 (41%)/67 (30%)
Egg 24/9 14/5 57/49 28/24 123 (55%)/87 (39%)
Soy 6/1* 5/1 16/9 7/3 34 (15%)/14 (6%)
Other legumes 2/0 2/1 5/5 0/0 9 (4%)/6 (3%)
Tree nuts 14/13 13/13 47/47 15/15 89 (40%)/88 (39%)
Wheat 5/1 4/0 16/11 7/5 32 (14%)/17 (8%) 
Shellfish 7/5 5/ 4 20/20 13/11 45 (20%)/40 (18%) 
Other 13/9 14/ 7 42/34 26/20 95 (43%)/70 (31%) 
Total 32 (67%)/28 (58%) 25 (68%)/20 (54%) 77 (79%)/75 (77%) 36 (88%)/36 (88%) 170 (76%)/159 (71%)
*This patient was offered a soy challenge but declined.
TABLE VI. Performance characteristics of the CAP-RAST at different cutoff values to predict a positive challenge result
RAST cutoff value Sensitivity (%) Specificity (%) PPV (%) NPV (%)
>0.35 kUA/L 83.8 33.3 49.2 72.7
≥2 kUA/L 54.1 72.7 60.6 67.3
≥5 kUA/L 24.3 89.6 64.3 60.6
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diagnosed by skin test or RAST only and who had never
been exposed to peanuts or had a clinical reaction. The
specificity and PPV of skin and RAST testing are quite
low, and in one report, only 33% of children whose aller-
gies were diagnosed by skin testing alone were found to
be truly peanut allergic.9 It is unlikely that the inclusion
of these children had a major effect on our results, how-
ever, because there was a similar percentage in each
group of patients. However, if we assume that only a
third of the 13 children in this group who passed their
challenge had true peanut allergy, and that all of these
children in the other groups had true peanut allergy, the
estimate would fall to as low as 17.5%.
PN-IgE levels were significantly lower in the group of
patients who passed the challenge (median 0.69) than in
those who failed (median 2.06) and those who could not
be challenged (median > 100). These levels are very dif-
ferent from those reported by Sampson and Ho8 in their
study examining the relationship between food-specific
IgE levels and challenge outcome. In that study, patients
with positive peanut challenge results had a median PN-
IgE of 47.2 kUA/L, compared with 2.0 kUA/L for
patients who had negative challenge results. These dif-
ferences are not surprising, however, because we did not
offer challenges to those with PN-IgE levels greater than
20 kUA/L, who were believed to almost certainly have
peanut allergy based on that prior study.
Overall, we found that PN-IgE levels were the best
guide to determine which patients should be considered
for a formal challenge. However, it should also be noted
there were 6 patients with negative RAST results and 2
with both negative RAST and skin test results who had
positive challenge results (1 open and 1 DBPCPC). The
reactions during challenge in this group varied from lim-
ited urticaria to multisystem involvement, which empha-
sizes the limitations of these test methods and the impor-
tance or performing all challenges in a controlled setting. 
Although many children did not have a RAST per-
formed at the time of diagnosis, the data on initial PN-
IgE levels that we do have suggest that these may also
provide valuable predictive information. Although the
initial PN-IgE levels were similar for those children who
passed and failed the challenge, when all children with
ongoing peanut allergy were included in the analysis, the
results were markedly different. A low initial PN-IgE
level therefore improves the odds of eventually outgrow-
ing peanut allergy, whereas a higher initial level was
associated with much poorer odds. In fact, only 2 of 54
(4%) patients with an initial PN-IgE level greater than 10
kUA/L outgrew their peanut allergy.
Initial reactions to peanut exposure also had some pre-
dictive value with regard to future peanut allergy status.
Patients who outgrew their allergies were significantly
more likely to have initial reactions involving only the
skin than those with ongoing peanut allergy. In addition,
patients with initial reactions involving 3 systems were
significantly more likely to have ongoing peanut allergy,
although 1 patient with such a reaction did outgrow his
peanut allergy. Twenty percent of the study population
had an initial reaction localized to the face only, many of
which involved only a few hives around the mouth.
Although we had anticipated that these children might be
the most likely to lose their reactivity, this did not appear
to be the case. 
Forty-one percent of the patients had a history of milk
allergy, and 55% had a history of egg allergy. An unex-
pected finding was that the patients in this study were far
less likely to have outgrown their milk and egg allergies
by the time they were 4 years or older (26% and 29%,
respectively), as compared with previous reports on the
natural history of milk and egg allergy.4-7 Future follow-
up will be needed to determine whether they remain
allergic to these foods or whether patients who have
peanut allergy tend to outgrow their associated food
allergies at a slower rate. As with other studies of peanut
allergy, many patients had an associated tree nut aller-
gy.10,11 In addition, we found a somewhat higher rate of
allergy to soy and other legumes (15%) than was previ-
ously reported in children with peanut allergy.12
Bock and Atkins2 reported an earlier study on the nat-
ural history of peanut allergy in 36 patients ranging in age
from 2 to 14 years in which no patients outgrew their
allergies. More recently, the idea of life-long peanut aller-
gy was challenged by Hourihane et al,7 who examined
patients with a clinical history of peanut allergy, begin-
ning at a median age of 11 months, in a case control study.
They found that 9.6% of patients who had restricted
peanuts from their diet were no longer allergic to peanuts.
In our study we found that a higher percentage of patients
outgrew their allergy to peanuts, most likely because the
patients who were challenged in our study were selected
by history and PN-IgE level rather than by history or par-
ent request and skin test result, as was done by Hourihane
et al. As in our study, they found that patients who out-
grew their peanut allergy had a lower rate of eczema and
were more likely to have outgrown other food allergies.
However, contrary to our data, their findings showed that
patients who outgrew peanut allergy also had lower rates
of asthma and allergic rhinitis.
We conclude that approximately 20% of children with
peanut allergy do outgrow their allergy. Although
patients with an initial PN-IgE level greater 10 kUA/L are
unlikely to outgrow their allergy, we would still recom-
mend rechecking PN-IgE levels for all patients on a year-
ly basis at least through the age of 4 years because we did
have 2 patients with high initial PN-IgE levels who out-
grew their allergy. Although some may question whether
it is ethical to challenge patients to a highly allergenic
food, the benefits provided to those who are shown to no
longer be allergic clearly outweigh the risks of a careful-
ly performed challenge. Although the ideal cutoff for
challenge eligibility has not been established, we have
shown that 61% of patients with a PN-IgE level less than
5 kUA/L and 67% with a PN-IgE level less than 2 kUA/L
had negative challenge results. We therefore recommend
that patients with peanut allergy who are older than 4
years and who have a PN-IgE level less than 5 kUA/L be
considered for a formal challenge in a hospital setting.
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